The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.
The firm's net loss swelled to $29.4 million as the newly public, pre-revenue company continued preparations to market its next-generation protein sequencing platform.
DNAStar has announced NovaFold AI, an update to its NovaFold protein structure prediction software that incorporates the AlphaFold 2 artificial intelligence system from DeepMind Technologies. The offering, billed as NovaFold AI powered by AlphaFold 2, lets users access the AlphaFold protein structure prediction method from within DNAStar's NovaCloud Services interface of the firm's Protean 3D visualization and analysis suite.
With new focus, the firm expects to grow its compound annual growth rate from 5.2 percent to 9 percent over the next few years.
The government of British Columbia will provide Genome BC with C$78 million in funding for genomics research in various areas under its 2022 budget.
Bruker has released its GPU-based PASER 2022 proteomics software for its timsTOF Pro 2, timsTOF SCP, and timsTOF flex mass spectrometers. The software package includes its TIMS DIA-NN software, which is tailored to high-throughput proteomics applications, as well as its TIMScore algorithm, which uses machine learning to predict the collisional cross-section (CCS) values of tryptic and phosphorylated peptides.
The Right Drug Dose Now Act seeks to address many of the barriers that have hindered integration of pharmacogenomic information into mainstream care.
INBRX-109 is currently being studied in advanced or metastatic conventional chondrosarcoma, pancreatic cancer, and malignant pleural mesothelioma.
Paragon Genomics has launched the CleanPlex Emerging Variant Add-on V2 (EVAv2) for its CleanPlex SARS-CoV-2 Research and Surveillance Panels for viral detection, mutation analysis, variant tracking, and epidemiological research. The add-on provides optimized coverage for new and emerging variants of SARS-CoV-2, Paragon said. It provides additional confidence in variant calling and includes added primers for enhanced coverage of critical variants, such as Alpha, Beta, Delta, Mu, and Omicron. EVAv2 has also been confirmed in silico to cover all defining and characteristic mutations of the sub-lineages of Omicron: BA.1, BA.2, and BA.3. The add-on has been designed for ease of use with existing CleanPlex SARS-CoV-2 whole-genome sequencing panels and can be directly added to existing CleanPLex workflows with minimal time and effort, the company said. In general, CleanPlex uses a proprietary multiplex PCR background cleaning chemistry to effectively remove non-specific PCR products, improving target enrichment performance and efficient use of sequencing reads.
Spatial mapping data, viral genetics, and other evidence suggest the coronavirus behind the COVID-19 pandemic spread from a Wuhan market through two initial transmission events.
PLOS Papers on Fragile X Mutation Effects, Overlapping Virus Open Reading Frames, Gecko Transcriptome
Researchers report on the consequences of fragile X syndrome-related mutations, catalogue overlapping open reading frames in viral genomes, and outline findings from a single-molecule real time sequencing-based analysis of the Tokay gecko transcriptome.
As its research business increasingly tilts toward oncology, the firm has cemented plans for its first clinical test launch this year.
Ahead of its sequencer launch next month, Element has been partnering to integrate the instrument with existing next-generation sequencing products.
Since launching the G4 sequencer in December, Singular Genomics has been busy partnering to situate the instrument in the existing next-generation sequencing ecosystem.
Last week, GenomeWeb's readers were most interested in new class action lawsuits filed against Natera.
Research published within the past three years highlights a unique role for proteomics to aid critical areas of unmet need in rare disease populations.
Both suits referenced a recent story in the New York Times about poor NIPT performance for rarer chromosomal abnormalities, especially microdeletions.
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Investigators identified 12 loci linked to the life-threatening cardiac arrhythmia condition, using TWAS, PheWAS, polygenic risk scoring, and other analyses to interpret these risk sites.